Brief: Nurix Therapeutics Presents Data From Studies Of Its Targeted Protein Degraders In B Cell Malignancies
14/06/2023 12:01
June 14 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS PRESENTS DATA FROM STUDIES OF ITS
TARGETED
PROTEIN DEGRADERS IN B CELL MALIGNANCIES AND INITIATES EXPANSION
OF NX-2127 PHASE 1B TRIAL IN DIFFUSE LARGE B CELL LYMPHOMA AND
MANTLE CELL LYMPHOMA INDICATIONS
Source text for Eikon: ID:nGNX3B8M5Z
Further company coverage: NRIX.O
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis